SEARCH

SEARCH BY CITATION

References

  • 1
    Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332: 581588.
  • 2
    Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1: Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826850.
  • 3
    Jee S, Tsai T, Tsai W et al. HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. Br J Dermatol 1998; 139: 978983.
  • 4
    Yip SY. The prevalence of psoriasis in the mongoloid race. J Am Acad Dermatol 1984; 10: 965968.
  • 5
    Kawada A, Tezuka T, Nakamizo Y et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003; 31: 5964.
  • 6
    Lebwohl M, Ali S. Treatment of psoriasis. Part 2: systemic therapies. J Am Acad Dermatol 2001; 45: 649661.
  • 7
    Menter MA, See JA, Amend WJ et al. Proceedings of the psoriasis combination and rotation therapy conference. Deer Valley, Utah, Oct. 7–9, 1994. J Am Acad Dermatol 1996; 34: 315321.
  • 8
    Gottlieb AB. Psoriasis. Immunopathology and immunomodulation. Dermatol Clin 2001; 19: 649657.
  • 9
    Salfeld J, Kupper H. Adalimumab. In: BoehnckeWH, RadekeHH eds. Biologics in General Medicine, 1st edn. New York: Springer-Verlag Berlin Heidelberg, 2007; 1431.
  • 10
    HUMIRA® [Prescribing Information]. North Chicago, IL: Abbott Laboratories, 2009.
  • 11
    Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598606.
  • 12
    Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106115.
  • 13
    Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558566.
  • 14
    Miyasaka N; CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 2008; 18: 252262.
  • 15
    Christophers E, Griffiths CE, Gaitanis G, Van De Kerkhof P. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol 2006; 20: 921925.
  • 16
    Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280284.
  • 17
    Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, Clinical and Functional Outcomes With Adalimumab (a Human Anti-TNF Monoclonal Antibody) in the Treatment of Patients With Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy: A Randomized, Placebo-Controlled, 52-Week Trial. Arthritis Rheum 2004; 50: 14001411.